Acumen Pharmaceuticals (NASDAQ:ABOS) Earns Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Acumen Pharmaceuticals (NASDAQ:ABOS – Free Report) in a research note published on Wednesday morning, Benzinga reports. The firm currently has a $15.00 target price on the stock. Acumen Pharmaceuticals Stock Performance Shares of NASDAQ ABOS traded down $0.04 during trading on Wednesday, hitting $3.76. The company […]

Related Keywords

Chicago ,Illinois ,United States , ,Acumen Pharmaceuticals ,Analyst Recommendations For Acumen Pharmaceuticals ,Jump Financial ,Intrepid Financial Planning Group ,Citigroup Inc ,Acumen Pharmaceuticals Stock Performance ,Sg Americas Securities ,Chicago Partners Investment Group ,Acumen Pharmaceuticals Inc ,News Ratings For Acumen Pharmaceuticals Daily ,Free Report ,Get Free Report ,Partners Investment Group ,Financial Planning Group ,Acumen Pharmaceuticals Daily ,